Breaking News, Collaborations & Alliances

MabVax, MSK, Juno Enter Antibody Discovery Pact

Will use MabVax platform to develop anti-cancer therapeutics

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

MabVax Therapeutics has entered into agreements with Memorial Sloan Kettering Cancer Center (MSK) and Juno Therapeutics for the development of antibody targeting therapeutic products derived from the fully-human antibodies discovered using its antibody discovery platform.   MabVax will supply targeting sequences from the fully-human antibodies to MSK, which will conduct early stage R&D of Chimeric Antigen Receptor (CAR) T-cell therapeutics using the MabVax antibody sequences with the goal o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters